3. Cumberbatch MGK, Foerster B, Catto JWF, Kamat AM, Kassouf W, Jubber I, et al. Repeat transurethral resection in non-muscleinvasive bladder cancer: a systematic review. Eur Urol 2018;73:925-33. PMID:
29523366
5. Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol 2019;76:639-57. PMID:
31443960
6. Svatek RS, Hollenbeck BK, Holmäng S, Lee R, Kim SP, Stenzl A, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 2014;66:253-62. PMID:
24472711
8. He D, Zeng C, Brinkley BR. Nuclear matrix proteins as structural and functional components of the mitotic apparatus. Int Rev Cytol 1995;162B:1-74. PMID:
8557485
9. Cho YH, Jung SI, Hwang EC. Novel and emerging surveillance markers for bladder cancer. In: Ku JH, editor. Bladder cancer. Cambridge (MA): Academic Press; 2018. pp. 599-612.
10. Hatzichristodoulou G, Kübler H, Schwaibold H, Wagenpfeil S, Eibauer C, Hofer C, et al. Nuclear matrix protein 22 for bladder cancer detection: comparative analysis of the BladderChek® and ELISA. Anticancer Res 2012;32:5093-7. PMID:
23155286
12. Lokeshwar VB, Schroeder GL, Selzer MG, Hautmann SH, Posey JT, Duncan RC, et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer 2002;95:61-72. PMID:
12115318
13. Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS, deVere White R, Sheinfeld J, et al. Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology 1997;50:349-53. PMID:
9301696
14. Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I. Noninvasive detection of bladder cancer with the BTA stat test. J Urol 1999;161:443-6. PMID:
9915422
15. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology 1997;50:882-7. PMID:
9426718
16. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 1999;161:1486-9. PMID:
10210378
17. Allard P, Fradet Y, Têtu B, Bernard P. Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder. Clin Cancer Res 1995;1:1195-202. PMID:
9815912
19. Pfister C, Chautard D, Devonec M, Perrin P, Chopin D, Rischmann P, et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 2003;169:921-4. PMID:
12576813
20. Laudadio J, Keane TE, Reeves HM, Savage SJ, Hoda RS, Lage JM, et al. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int 2005;96:1280-5. PMID:
16287445
21. Friedrich MG, Toma MI, Hellstern A, Pantel K, Weisenberger DJ, Noldus J, et al. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int 2003;92:911-4. PMID:
14632845
22. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 2008;26:646-51. PMID:
18367109
23. Dimashkieh H, Wolff DJ, Smith TM, Houser PM, Nietert PJ, Yang J. Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Cancer Cytopathol 2013;121:591-7. PMID:
23801650
27. Khetrapal P, Lee MWL, Tan WS, Dong L, de Winter P, Feber A, et al. The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: a systematic review. Cancer Treat Rev 2018;66:56-63. PMID:
29684744
29. Brunner A, Prelog M, Verdorfer I, Tzankov A, Mikuz G, Ensinger C. EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. J Clin Pathol 2008;61:307-10. PMID:
17586680
33. Gazzaniga P, de Berardinis E, Raimondi C, Gradilone A, Busetto GM, De Falco E, et al. Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. Int J Cancer 2014;135:1978-82. PMID:
24599551
34. Abrahamsson J, Aaltonen K, Engilbertsson H, Liedberg F, Patschan O, Rydén L, et al. Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: association with tumor stage, lymph node metastases, FDG-PET findings, and survival. Urol Oncol 2017;35:606.e9-16. PMID:
28676151
35. Haga N, Tsubouchi K, Maruta H, Koguchi T, Hoshi S, Ogawa S, et al. Increase in circulating tumor cells in invasive bladder cancer after transurethral resection of bladder tumor. Anticancer Res 2020;40:4299-307. PMID:
32727757
37. Wang XS, Zhao MQ, Zhang L, Kong DJ, Ding XZ, Hu XC, et al. Cell-free DNA in blood and urine as a diagnostic tool for bladder cancer: a meta-analysis. Am J Transl Res 2018;10:1935-48. PMID:
30093933
38. Oxnard GR, Paweletz CP, Sholl LM. Genomic analysis of plasma Cell-Free DNA in patients with cancer. JAMA Oncol 2017;3:740-1. PMID:
27541382
41. Valenzuela MT, Galisteo R, Zuluaga A, Villalobos M, Núñez MI, Oliver FJ, et al. Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer. Eur Urol 2002;42:622-8 discussion 628-30. PMID:
12477660
42. Ellinger J, El Kassem N, Heukamp LC, Matthews S, Cubukluoz F, Kahl P, et al. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J Urol 2008;179:346-52. PMID:
18006010
43. Millis SZ, Bryant D, Basu G, Bender R, Vranic S, Gatalica Z, et al. Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin. Clin Genitourin Cancer 2015;13:e37-49. PMID:
25178641
47. Green EA, Li R, Albiges L, Choueiri TK, Freedman M, Pal S, et al. Clinical utility of cell-free and circulating tumor dna in kidney and bladder cancer: a critical review of current literature. Eur Urol Oncol 2021;4:893-903. PMID:
33975782
48. Mai S, Zhang Z, Mi W. Upregulation of circ_PVT1 and circ_001569 indicate unfavorable prognosis in colorectal cancer. Ann Clin Lab Sci 2021;51:55-60. PMID:
33653781
49. Jiang X, Du L, Wang L, Li J, Liu Y, Zheng G, et al. Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Int J Cancer 2015;136:854-62. PMID:
24961907
51. Motawi TK, Rizk SM, Ibrahim TM, Ibrahim IA. Circulating microRNAs, miR-92a, miR-100 and miR-143, as non-invasive biomarkers for bladder cancer diagnosis. Cell Biochem Funct 2016;34:142-8. PMID:
26916216
53. Marín-Aguilera M, Mengual L, Ribal MJ. Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer. Urology 2012;79:240.e9-15. PMID:
22055693
54. Gazzaniga P, Gandini O, Giuliani L, Magnanti M, Gradilone A, Silvestri I, et al. Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients. Clin Cancer Res 2001;7:577-83. PMID:
11297251
55. Angulo JC, Ferruelo A, Rodríguez-Barbero JM, Núñez C, de Fata FR, González J. Detección y estadificación molecular del cáncer vesical mediante RT-PCR a tiempo real para gelatinasas (MMP-2, MMP-9) y TIMP-2 en sangre periférica [Detection and molecular staging of bladder cancer using real-time RT-PCR for gelatinases (MMP-2, MMP-9) and TIMP-2 in peripheral blood]. Actas Urol Esp 2011;35:127-36. PMID:
21334102
56. Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C. Exosomal-like vesicles are present in human blood plasma. Int Immunol 2005;17:879-87. PMID:
15908444
58. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science 2020;367:eaau6977. PMID:
32029601
62. Zhang S, Du L, Wang L, Jiang X, Zhan Y, Li J, et al. Evaluation of serum exosomal LncRNA-based biomarker panel for diagnosis and recurrence prediction of bladder cancer. J Cell Mol Med 2019;23:1396-405. PMID:
30467945
64. Yan L, Li Q, Sun K, Jiang F. MiR-4644 is upregulated in plasma exosomes of bladder cancer patients and promotes bladder cancer progression by targeting UBIAD1. Am J Transl Res 2020;12:6277-89. PMID:
33194029
69. Graça G, Lau CE, Gonçalves LG. Exploring cancer metabolism: applications of metabolomics and metabolic phenotyping in cancer research and diagnostics. Adv Exp Med Biol 2020;1219:367-85. PMID:
32130709
70. Bansal N, Gupta A, Mitash N, Shakya PS, Mandhani A, Mahdi AA, et al. Low- and high-grade bladder cancer determination via human serum-based metabolomics approach. J Proteome Res 2013;12:5839-50. PMID:
24219689
73. Bansal N, Gupta A, Sankhwar SN, Mahdi AA. Low- and highgrade bladder cancer appraisal via serum-based proteomics approach. Clin Chim Acta 2014;436:97-103. PMID:
24875752
74. Bansal N, Gupta AK, Gupta A, Sankhwar SN, Mahdi AA. Serum-based protein biomarkers of bladder cancer: a pre- and post-operative evaluation. J Pharm Biomed Anal 2016;124:22-5. PMID:
26922578
76. Allione A, Pardini B, Viberti C, Giribaldi G, Turini S, Di Gaetano C, et al. MMP23B expression and protein levels in blood and urine are associated with bladder cancer. Carcinogenesis 2018;39:1254-63. PMID:
30052775
77. López-Cortés R, Gómez BB, Vázquez-Estévez S, Pérez-Fentes D, Núñez C. Blood-based protein biomarkers in bladder urothelial tumors. J Proteomics 2021;247:104329. PMID:
34298186
79. Dahmcke CM, Steven KE, Larsen LK, Poulsen AL, Abdul-Al A, Dahl C, et al. A prospective blinded evaluation of urine-dna testing for detection of urothelial bladder carcinoma in patients with gross hematuria. Eur Urol 2016;70:916-9. PMID:
27417036
80. van Kessel KE, Beukers W, Lurkin I, Ziel-van der Made A, van der Keur KA, Boormans JL, et al. Validation of a DNA methylation-mutation urine assay to select patients with hematuria for cystoscopy. J Urol 2017;197(3 Pt 1):590-5. PMID:
27746284
81. Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005;23:2903-10. PMID:
15753461
82. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59. PMID:
18337604
84. van der Heijden AG, Mengual L, Ingelmo-Torres M, Lozano JJ, van Rijt-van de Westerlo CCM, Baixauli M, et al. Urine cell-based DNA methylation classifier for monitoring bladder cancer. Clin Epigenetics 2018;10:71. PMID:
29854012
85. Renard I, Joniau S, van Cleynenbreugel B, Collette C, Naômé C, Vlassenbroeck I, et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylationspecific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol 2010;58:96-104. PMID:
19674832
87. Hauser S, Kogej M, Fechner G, VON Pezold J, Vorreuther R, Lümmen G, et al. Serum DNA hypermethylation in patients with bladder cancer: results of a prospective multicenter study. Anticancer Res 2013;33:779-84. PMID:
23482744
89. Springer SU, Chen CH, Rodriguez Pena MDC, Li L, Douville C, Wang Y, et al. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. Elife 2018;7:e32143. PMID:
29557778
90. Beukers W, van der Keur KA, Kandimalla R, Vergouwe Y, Steyerberg EW, Boormans JL, et al. FGFR3, TERT and OTX1 as a urinary biomarker combination for surveillance of patients with bladder cancer in a large prospective multicenter study. J Urol 2017;197:1410-8. PMID:
28049011
91. Birkenkamp-Demtröder K, Nordentoft I, Christensen E, Høyer S, Reinert T, Vang S, et al. Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol 2016;70:75-82. PMID:
26803478